Articles tagged "Kidney transplantation"

2017 American Transplant Congress
The Incremental of Cost of Incompatible Living Donor Kidney Transplant: A National Cohort Analysis.
D. Axelrod,¹ K. Lentine,² M. Schnitzler,² H. Xiao,² X. Lou,³ B. Orandi,³ J. Garonzik Wang,³ A. Massie,³ D. Segev.³
¹Surgery, East Carolina University, Greenville, NC; ²Transplant, Saint Louis University, St. Louis, MO; ³Surgery, Johns Hopkins University, Baltimore, MD
Incompatible living donor kidney transplant (ILDKT) has been established as an effective option for patients with willing but human leukocyte antigen incompatible live donors, reducing…
2017 American Transplant Congress
Impact of Dialysis During the Transplant Admission on Transplant and Post-Transplant Cost of Care.
J. Tao,¹ C. Horstman,¹ W. Bannister,¹ M. Schnitzler,² F. Irwin,¹ A. Bonagura,¹ B. Laihinen.¹
¹Complex Medical Conditions, Optum, UnitedHealth Group, Eden Prairie, MN; ²Surgery, St Louis University, St Louis, MO
This study examines the impact of dialysis during the transplant admission on total cost of transplant and one year post-transplant care for kidney, liver, and…
2017 American Transplant Congress
mTOR Inhibition Diminishes Peripheral Blood CD8⁺CD28^–CD38^hi Effector/Memory T Cells and Facilitates Resolution of Belatacept-Refractory Kidney Rejection.
C. Castro-Rojas,¹ A. Godarova,¹ A. Leino,² R. Alloway,² M. Jordan,³ E. Woodle,² D. Hildeman.¹
¹Division of Immunobiology, Cincinnati Children's Hospital, University of Cincinnati College of Medicine, Cincinnati, OH; ²Division of Transplantation, University of Cincinnati College of Medicine, Cincinnati, OH; ³Division of Bone Marrow Transplant and Immune Deficiency, Cincinnati Children's Research Foundation, Cincinnati, OH
Belatacept, a CD28-CD80/86 blocker, was approved by the FDA to provide immunosuppression without nephrotoxicity or cardiovascular and metabolic adverse effects. As part of our multi-center…
2017 American Transplant Congress
HLA Eplet Mismatches Predict DSA Formation, Graft Survival, and Re-Transplantation Rate in Pediatric Renal Transplantation.
M. Sypek,^1,2 S. Hiho,³ L. Cantwell,³ P. Hughes,² A. Le Page,⁴ J. Kausman.¹
¹Royal Children's Hospital, Melbourne, Australia; ²Royal Melbourne Hospital, Melbourne, Australia; ³Victorian Transplant and Immunogenetics Service, Melbourne, Australia; ⁴Monash Children's Hospital, Melbourne, Australia
The potential benefits of HLA epitope based matching are greatest for pediatric recipients, however, there is little published data on the association of epitope mismatches…
2017 American Transplant Congress
A Prospective Iterative Trial of Carfizomib-Based Desensitization Trial: Initial Comparative Observations.
S. Tremblay,¹ A. Shields,^1,2 R. Alloway,¹ P. Brailey,¹ A. Leino,¹ A. Lichvar,¹ B. Abu Jawdeh,¹ J. Driscoll,¹ A. Girnita,¹ E. Woodle.¹
¹U of Cincinnati, Cincinnati; ²Christ Hospital, Cincinnati
Carfilzomib (CFZ) is a 2nd generation proteasome inhibitor different form bortezomib in that it irreversibly disables 20s and 26s proteasomes.Results from the first 2 phases…
2017 American Transplant Congress
Post-Transplant Reduction in Pre-Existing Donor-Specific Antibody Levels After Belatacept- vs Cyclosporine-Based Immunosuppression.
R. Bray,¹ H. Gebel,¹ R. Townsend,² M. Polinsky,² L. Yang,² U. Meier-Kriesche,² C. Larsen.¹
¹Emory University, Atlanta, GA; ²Bristol-Myers Squibb, Lawrenceville, NJ
Purpose: We explored the effect of belatacept (bela)- and cyclosporine (CsA)-based immunosuppression (IS) on pre-existing donor-specific antibody (DSA) levels by mean fluorescence intensity (MFI) in…
2017 American Transplant Congress
Dementia and Alzheimer's Disease Among Older Kidney Transplant Recipients.
M. McAdams DeMarco, S. Bae, N. Chu, A. Gross, C. Brown IV, E. Oh, P. Rosenberg, K. Neufeld, R. Varadhan, M. Albert, J. Walston, D. Segev.
Johns Hopkins, Baltimore, MD
Background: Kidney transplantation (KT) is a growing treatment option for older ESRD patients. Older recipients may develop post-KT dementia and Alzheimer's disease (AD) associated with…
2017 American Transplant Congress
The Impact of the New Kidney Allocation System on Length of Dialysis Prior to Transplantation.
T. Melanson,¹ M. Basu,¹ L. Plantinga,¹ S. Pastan,¹ S. Mohan,² R. Patzer.¹
¹Emory University, Atlanta; ²Columbia University, New York
Introduction: The Kidney Allocation System (KAS) changed the starting point for calculating waiting time for patients on the kidney transplant (KTx) waitlist from the time…
2017 American Transplant Congress
Gene Expression During Development of Chronic Antibody-Mediated Rejection in Renal Allografts from Non-Human Primates: Validation of Markers Used in Humans and Sequential Changes in Protocol Biopsies.
B. Adam,¹ R. Smith,² M. Matsunami,² I. Rosales,² B. Afzali,¹ T. Oura,² A. Cosimi,² T. Kawai,² R. Colvin,² M. Mengel.¹
¹University of Alberta, Edmonton, Canada; ²Harvard Medical School and Massachusetts General Hospital, Boston
Background: RNA transcript measurement is a promising adjunct for the diagnosis and classification of antibody-mediated rejection (ABMR), however most technologies require specially processed biopsy samples.…
2017 American Transplant Congress
Gut Microbiota-Urinary Tract Infection Axis in Kidney Transplant Recipients.
J. Lee,¹ M. Mcgruder,¹ L. Zhang,¹ D. Dadhania,¹ M. Thangamani,¹ L. Ling,² Y. Taur,² E. Pamer,² M. Suthanthiran.¹
¹Medicine, Weill Cornell, New York, NY; ²Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
Introduction. The gut microbiota has recently been identified as a risk factor for development of infectious complications like bacteremia; herein, we evaluated the relationship between…